The majority of alliances today are based on the Company’s HuCAL antibody technology. HuCAL is available for licensing for research and diagnostic applications as well as for therapeutic antibody generation against targets in the infectious disease space.
New Technologies
With the acquisition of Sloning BioTechnology in 2010, MorphoSys became the sole provider of the precise combinatorial protein libraries that can be made with the Slonomics platform. Combining the Slonomics system with MorphoSys’ technologies and broad expertise in antibody library design, the Company is staying at the forefront of technology development and has established arYla, a cutting-edge platform for antibody optimization.
MorphoSys is looking for selected partnerships based on the Slonomics and arYla technology platforms.
